---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006692"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:36:58.722944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ZyVersa amends license agreement with L&F Research, waives termination rights on $1.5M milestone payments

## Summary
- LFR waives termination rights for $1M milestone payments until March 31, 2023, contingent on ZyVersa forgiving $351,579 note and paying $648,421 cash.
- LFR waives termination rights for $500K milestone payment until Jan 31, 2024 or 10 days after ZyVersa raises $30M equity.
- ZyVersa to forgive $351,579 promissory note from LFR as part of consideration for the waiver.
- Put option agreement between ZyVersa and LFR will expire upon forgiveness of the note.
- If conditions not met, waivers become void and original payment obligations reinstated.

## SEC filing metadata
- accession: 0001493152-23-006692
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223006692/0001493152-23-006692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223006692/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006692
- JSON: https://secwatch.observer/filing/0001493152-23-006692.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006692.txt

## Key facts
- Material Agreements
  ZyVersa Therapeutics, Inc. amended Amendment and Restatement Agreement with L&F Research LLC (LFR) (effective 2023-02-28).
  - Action: amendment
  - Agreement: license
  - Counterparty: L&F Research LLC (LFR)
  - Effective: 2023-02-28
  source text: On February 28, 2023, ZyVersa Therapeutics, Inc., a Delaware corporation (the "Company") and LFR entered into an Amendment and Restatement Agreement (the "Restatement"), amending and restating the previously disclosed Waiver of Certain Rights Under License Agreement, dated March 2, 2022, by and between ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa") and LFR, as amended (the "Waiver Agreement").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223006692/0001493152-23-006692-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.